|
|
|
|
| LEADER |
09557nam a22004573i 4500 |
| 001 |
EBC6942718 |
| 003 |
MiAaPQ |
| 005 |
20231204023222.0 |
| 006 |
m o d | |
| 007 |
cr cnu|||||||| |
| 008 |
231204s2022 xx o ||||0 eng d |
| 020 |
|
|
|a 9783030926120
|q (electronic bk.)
|
| 020 |
|
|
|z 9783030926113
|
| 035 |
|
|
|a (MiAaPQ)EBC6942718
|
| 035 |
|
|
|a (Au-PeEL)EBL6942718
|
| 035 |
|
|
|a (OCoLC)1309289043
|
| 040 |
|
|
|a MiAaPQ
|b eng
|e rda
|e pn
|c MiAaPQ
|d MiAaPQ
|
| 050 |
|
4 |
|a R723-723.7
|
| 100 |
1 |
|
|a Bremer, Anne.
|
| 245 |
1 |
0 |
|a Precision Oncology and Cancer Biomarkers :
|b Issues at Stake and Matters of Concern.
|
| 250 |
|
|
|a 1st ed.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing AG,
|c 2022.
|
| 264 |
|
4 |
|c ©2022.
|
| 300 |
|
|
|a 1 online resource (288 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Human Perspectives in Health Sciences and Technology Series ;
|v v.5
|
| 505 |
0 |
|
|a Intro -- Preface: What Is Responsible Cancer Research? -- Anticipatory and Reflexive - The Importance of Sociotechnical Imaginaries -- Inclusive - The Relationship to the Public -- Responsive - Are There Any Roads from Criticism to Action? -- References -- Acknowledgements -- Contents -- Introduction -- References -- Introduction to the Imaginary of Precision Oncology -- Precision Medicine - Tradition, Evidence, Reason and Ambition -- Precision Oncology - Expectations and Realisations -- Precision Medicine and the Complexity of Biological Systems -- The Imaginary of Precision Medicine and Unintended Consequences -- References -- Precision Oncology in the News -- Introduction -- Framing Within the News Media -- Identifying Frames Within the Discourse on Priority-Setting and Cancer -- Precision Medicine as a Medical Revolution -- Discussion -- Why Have the Premises Remained Unchallenged? -- Cancer and Cancer Research: An Issue of More Than Tragic Choices? -- Alternative Imaginaries -- Lack of Nuance in the Field of Cancer and Cancer Research: Why? -- Conclusion -- References -- Cancer Currencies: Making and Marketing Resources in a First-in-Human Drug Trial in Denmark -- Introduction -- Cancer Currencies and Trial Qualities -- Unit One : A Research Business at the Heart of a Public Hospital -- Fast-Tracking Trialling at the Unit -- Competitive Enrolment -- Producing Good Care and Good Science Fast -- The Genomic Project: An Investment in Potentiality -- Research Bodies: High Patient Compliance -- Discussion -- References -- "Reconstruction of Trouble" -- Introduction: The Special Status of Breast Cancer in Society -- A Case Study of How Breast Reconstruction Was Prioritised, and the Unintended Consequences This Had for Breast Cancer Patients and Other Patient Groups -- The Actors and Their Roles in the Prioritisation Game.
|
| 505 |
8 |
|
|a Debate, Decision-Making and Their Consequences -- References -- Lost in Translation -- A Short Introduction to Health, Illness and Disease in the Context of Ovarian Cancer -- Perspectives and Concepts of Disease and Illness in Health -- A Brief Introduction to Ovarian Cancer - "The Silent Killer" -- Biomarkers in Epithelial Ovarian Cancer -- The Journey and Trajectory of Ovarian Cancer -- Anne - The Suspicion of Something Being Wrong -- Intermission - Moving from Illness to Disease: Classifying Ovarian Cancer -- Anne - The Preliminary Diagnosis -- Anne - Her Experienced Symptoms Confirmed into a Diagnosis -- Jenny - The Gynaecological Oncologist Meeting Her Patient Anne -- Anne - Accepting the Decision of Surgery -- Jenny - Posing a Final Diagnosis -- Anne - The Start of Chemotherapy -- Intermission - The Dichotomy Between Illness and Disease at the Diagnosis Stage -- Anne - The Meaning of Relapse -- Jenny - Telling the Truth or Giving False Hope? -- Anne - Towards the End of Her Journey -- Intermission - The Dichotomy Between Illness and Disease at the Stage of Relapse -- Anne - Accepting the Inevitable -- The Future of Ovarian Cancer: Anne's Story in 2040 -- Intermission - The Dichotomy Between Illness and Disease in an Era of Precision Medicine -- The Challenges of Communicating Illness, Disease and Health Between Patients and Clinicians -- Making Sense of and Finding Meaning Around Health, Illness and Disease -- The Meaning and Sense of Biomarkers - From a Patient Perspective -- Conclusion -- References -- HER2 Revisited: Reflections on the Future of Cancer Biomarker Research -- Introduction -- The HER2 Story -- Discovery and Basic Studies -- Biomarker Development -- Early Clinical Trials -- Revisiting the Story of HER2 -- How the HER2 Story Began: Oncogene Research Gathering Steam as a 'Bandwagon'.
|
| 505 |
8 |
|
|a Understanding the Social, Ethical and Economic Implications of the HER2/Oncogene Bandwagon -- Basic Science -- Diagnostic -- Treatment -- Where Are We Now? The Imaginary of Precision Oncology -- Conclusion -- References -- The Dynamics of the Labelling Game: An Essay On FLT3 Mutated Acute Myeloid Leukaemia -- References -- Crossing the Styx: If Precision Medicine Were to Become Exact Science -- Introduction -- Types of Models -- Understanding the Purpose of Formal Models -- Unification -- Prediction -- System Wide Models: Descriptive Models and Repositories of Information -- Explanation -- A Possible Tension Between the Requirements of Formal Models and the Need for Conceptual Flexibility and Ambiguity in Discovery -- The Modelling Process: The Challenges of Radical Openness and Contextuality -- A Drive Towards Computational Models -- Crossing the Styx -- References -- Publication Bias in Precision Oncology and Cancer Biomarker Research -- Challenges and Possible Implications -- Introduction -- Evidence of Publication Bias in Medical Research -- Publication Bias in Precision Oncology and Cancer Biomarker Research -- The Impact of Publication Bias on the Validity of the Scientific Literature and Contribution to the Reproducibility Crisis -- Discussion: Publication Bias in Precision Oncology and Cancer Biomarker Research -- Implications and Reflections on the Deeper Roots of the Problem -- Implications for Patients, Decision-Making in Clinical Practice and Socio-economic Aspects -- Implications for Researchers and the Scientific Community -- Reflecting on the Roots of the Problem of Publication Bias -- Conclusion -- References -- Assessing the Cost-Effectiveness of Molecular Targeted Therapies and Immune Checkpoint Inhibitors -- Introduction -- Economic Evaluation of Targeted Therapies and Checkpoint Inhibitors.
|
| 505 |
8 |
|
|a Arrangements Specific to Decision Making Involving Oncology Medicines -- Conclusions -- References -- Real-World Data in Health Technology Assessment: Do We Know It Well Enough? -- Introduction: The Growing Importance of Data in Health Care -- Real-World Data and Big Data: Some Definitions -- Health Technology Assessment in the Era of Information Technology -- Opportunities Related to Using RWD in HTA -- Challenges of Using RWD in HTA -- What Is Next: Do We Want RDW in HTA Be the Cynosure of All Eyes? -- References -- Just Caring: Precision Health vs. Ethical Ambiguity: Can we Afford the Ethical and Economic Costs? -- Just Caring: Cancer, Targeted Therapies, and Cost Control -- Cancer: Finding the First Cell/Preventing Future Cells -- Trading off Identified Lives and Statistical Lives: Ethical Issues -- Can We Just Abandon Metastatic Cancer Patients to Save Money? -- The Transition Challenge: Efficiency versus Compassion -- Whole Genome Sequencing: Another Precision Health Ethical Challenge -- Rational Democratic Deliberation: Not Precision Ethics But "Roughly Just" -- References -- Rationing of Personalised Cancer Drugs: Rethinking the Co-production of Evidence and Priority Setting Practices -- Introduction -- Personalised Cancer Care Increases the Health Gap -- Why Plan A Might Not Work and Why the Problem Is Connected to Biomarkers -- The Co-production Perspective as an Analytic Tool -- Sustainable Future Imaginaries for Cancer Drug Priority Setting -- References -- Filled with Desire, Perceive Molecules -- Prologue: The Desire to Help -- Acute Myeloid Leukaemia -- Filled with Desire, Find the Molecule -- AML Is a Name -- Empty of Desire, Perceive Mystery -- References -- Conclusions: The Biomarkers That Could Be Born -- The Biomarkers That Cannot Be Born: The Unsustainable Political Economy of Cancer Research.
|
| 505 |
8 |
|
|a Precision Oncology: Cartesian Dream or Nightmare? -- From Precision to Personalized Oncology: Biomarkers for Dignity? -- References -- Index.
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources.
|
| 590 |
|
|
|a Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2023. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Strand, Roger.
|
| 776 |
0 |
8 |
|i Print version:
|a Bremer, Anne
|t Precision Oncology and Cancer Biomarkers
|d Cham : Springer International Publishing AG,c2022
|z 9783030926113
|
| 797 |
2 |
|
|a ProQuest (Firm)
|
| 830 |
|
0 |
|a Human Perspectives in Health Sciences and Technology Series
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/matrademy/detail.action?docID=6942718
|z Click to View
|
